L-161,982 Chemical Properties

Density 

1.37±0.1 g/cm3(Predicted)

storage temp. 

2-8°C

solubility 

DMSO: soluble15mg/mL, clear

form 

powder

pka

4.57±0.10(Predicted)

color 

white to beige

Safety Information

WGK Germany 

3

L-161,982 Usage And Synthesis

Description

Prostaglandin E₂ (PGE₂) exerts its effects through four separate G coupled-protein receptors (EP_1-4). L-161,982 is a potent and selective EP₄ receptor antagonist. It demonstrates selective binding to human EP₄ receptors with a K_i value of 0.024 μM compared to other receptors of the prostanoid family, EP₁, EP₂, EP₃, DP, FP, and IP, with K_i values of 17, 23, 1.9, 5.1, 5.6, and 6.7 μM, respectively. L-161,982 at 10 mg/kg/day suppresses PGE₂-stimulated bone formation in young rats and at 100 nM reverses the anti-inflammatory action of PGE₂ in LPS-activated human macrophages. At 10 μM L-161982 blocks PGE₂-induced cell proliferation in HCA-7 colon cancer cells.

Uses

L-161,982 is an EP4 receptor antagonist, which blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells.

Definition

ChEBI: N-[2-[4-[[3-butyl-5-oxo-1-[2-(trifluoromethyl)phenyl]-1,2,4-triazol-4-yl]methyl]phenyl]phenyl]sulfonyl-3-methyl-2-thiophenecarboxamide is a member of biphenyls.

Biological Activity

EP 4 receptor antagonist that is selective over all other members of the prostanoid receptor family (K i values are 0.024, 0.71, 1.90, 5.10, 5.63, 6.74, 19 and 23 μ M for human EP 4 , TP, EP 3 , DP, FP, IP, EP 1 and EP 2 receptors respectively). Suppresses PGE 2 -induced bone formation in rats and prevents the nociceptive response induced by misoprostol in formalin-injected mice.

Biochem/physiol Actions

L-161,982 is a potent EP4 receptor antagonist that is selective over all other members of the prostanoid receptor family (Ki values are 0.024, 0.71, 1.90, 5.10, 5.63, 6.74, 19 and 23 μM for human EP4, TP, EP3, DP, FP, IP, EP1 and EP2 receptors respectively.

storage

Desiccate at +4°C

References

[1] M. MACHWATE. Prostaglandin receptor EP(4) mediates the bone anabolic effects of PGE(2).[J]. Molecular Pharmacology, 2001, 60 1 1: 36-41. DOI: 10.1124/mol.60.1.36
[2] KIYOSHI TAKAYAMA. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor.[J]. The Journal of Biological Chemistry, 2002, 277 46: 44147-44154. DOI: 10.1074/jbc.m204810200
[3] DURGA PRASAD CHERUKURI . The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells[J]. Experimental cell research, 2007, 313 14: Pages 2969-2979. DOI: 10.1016/j.yexcr.2007.06.004
[4] ANG LIN. TLR4 signaling promotes a COX-2/PGE2/STAT3 positive feedback loop in hepatocellular carcinoma (HCC) cells[J]. Oncoimmunology, 2015, 5 1. DOI: 10.1080/2162402x.2015.1074376

L-161,982(147776-06-5)Related Product Information

• CJ-21058
• GW 627368X
• CJ-42794
• Grapiprant
• PROSTAGLANDIN F1ALPHA
• Latanoprost
• Misoprostol Acid
• ONO-AE3-208
• 13,14-DIHYDROPROSTAGLANDIN E1
• Prostaglandin F2a
• PROSTAGLANDIN D2
• 6(R)-(4-CARBOXYPHENYLTHIO)-5(S)-HYDROXY-7(E),9(E),11(Z),14(Z)-EICOSATETRAENOIC ACID
• 11BETA-PROSTAGL AND IN F2ALPHA
• LEUKOTRIENE B4 DIMETHYL AMIDE
• LEUKOTRIENE D4
• CJ 033466
• L-161,982
• 4,5-DIETHYL-2,4-DIHYDRO 1,2,4-TRIAZOL-3 ONE